Follicular maturation and luteinisation

Indication for Choriogonadotropin alpha

Population group: Suitable for women, only adults (18 - 65 years old)
Therapeutic intent: Adjunct - intent

Choriogonadotropin alpha is indicated in the treatment of adult women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Choriogonadotropin alpha is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth.

For this indication, competent medicine agencies globally authorize below treatments:

250 ug once

Route of admnistration

Subcutaneous

Defined daily dose

250 - 250 ug

Dosage regimen

From 250 To 250 ug once every day

Detailed description

The maximum dose is 250 micrograms. The following dose regimen should be used in women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): One pre-filled syringe of choriogonadotropin alpha (250 micrograms) is administered 24 to 48 hours after the last administration of a follicle stimulating hormone (FSH) or human menopausal gonadotropin (hMG) preparation, i.e. when optimal stimulation of follicular growth is achieved.

Active ingredient

The principal pharmacodynamic activity in women is oocyte meiosis resumption, follicular rupture (ovulation), corpus luteum formation and production of progesterone and estradiol by the corpus luteum.

Read more about Choriogonadotropin alpha

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner